MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
AbCellera Biologics ROA Ratio 2011-2025 | ABCL
Annual ROA Ratio AbCellera Biologics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.97 | -9.84 | 10.29 | 11.64 | 11.83 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.83 | -11.97 | 2.39 |
Quarterly ROA Ratio AbCellera Biologics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.75 | -13.21 | -13.35 | -9.06 | -10.95 | -9.17 | -8.55 | -6.56 | -4.84 | -1.23 | 0.33 | 11.88 | 10.05 | 6.51 | 6.74 | 8.36 | 8.09 | 9.65 | 10.52 | 0.19 | 0.19 | 0.46 | -0.21 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.88 | -13.75 | -0.78 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-50.45 | $ 4.75 | -0.84 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-59.94 | $ 3.01 | -1.15 % | $ 233 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-34.19 | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-49.57 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 0.24 | 35.16 % | $ 522 M |  Israel |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 1.14 | -2.56 % | $ 6.22 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 210.29 | -1.18 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-154.77 | $ 0.52 | -44.24 % | $ 144 K | USA |
 |
Celldex Therapeutics
CLDX
|
-19.92 | $ 26.14 | -2.57 % | $ 1.68 M | USA |
 |
Cellectar Biosciences
CLRB
|
-354.19 | $ 2.6 | -5.8 % | $ 31.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.09 | -0.16 % | $ 7.43 B |  Australia |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
-81.36 | $ 1.2 | -5.91 % | $ 1.77 M | USA |
 |
Athersys
ATHX
|
-144.48 | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-40.29 | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 94.48 | -0.58 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
10.11 | $ 26.87 | 0.21 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-10.89 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
-30.55 | $ 9.5 | 0.16 % | $ 139 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-104.83 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-43.36 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
2.77 | $ 15.4 | 0.1 % | $ 2 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-78.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
-177.73 | - | -10.95 % | $ 876 K | USA |
 |
Eton Pharmaceuticals
ETON
|
-2.95 | $ 16.87 | -0.71 % | $ 433 M | USA |
 |
Axon Enterprise
AXON
|
8.43 | $ 580.0 | -1.89 % | $ 43.9 B | USA |
 |
Evogene Ltd.
EVGN
|
-39.9 | $ 1.03 | -1.9 % | $ 27.9 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Exelixis
EXEL
|
17.68 | $ 46.44 | -0.15 % | $ 13.5 B | USA |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.5 | -1.19 % | $ 15.7 M | USA |
 |
AstraZeneca PLC
AZN
|
0.11 | $ 92.68 | 0.25 % | $ 96.9 B | Britain |
|
Foghorn Therapeutics
FHTX
|
-30.5 | $ 5.37 | -0.56 % | $ 295 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
-73.35 | $ 12.3 | -0.57 % | $ 810 M | USA |